Lemborexant
Clinical data | |
---|---|
Trade names | Dayvigo |
Other names | E-2006 |
License data |
|
Pregnancy category | |
Routes of administration | By mouth[3] |
Drug class | Orexin receptor antagonist; Hypnotic; Sedative |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Good (≥87%)[5][6] |
Protein binding | 94%[3] |
Metabolism | Liver (major: CYP3A4, minor: CYP3A5)[3] |
Metabolites | M10[3] |
Elimination half-life | 17–19 hours or 55 hours[3][7] |
Excretion | Feces: 57.4%[3] Urine: 29.1%[3] |
Identifiers | |
| |
JSmol) | |
| |
|
Lemborexant, sold under the brand name Dayvigo, is an
Lemborexant was approved for medical use in the United States in December 2019.
Medical uses
Lemborexant is used in the treatment of insomnia in adults.[3]
A major
Compared to
Available forms
Lemborexant is available in the form of 5 and 10 mg
Side effects
Lemborexant at doses of 10, 20, and 30 mg produces
Pharmacology
Pharmacodynamics
Lemborexant is a dual
Pharmacokinetics
The
Although lemborexant has a longer
History
In June 2016, Eisai initiated Phase III clinical trials in the United States, France, Germany, Italy, Japan, Poland, Spain and the UK.[22]
In December 2019, lemborexant was approved for use in the United States based on results from the SUNRISE 1 and SUNRISE 2 Phase III clinical trials.[11][23]
Society and culture
Names
Lemborexant is the
Availability
Lemborexant is marketed in the United States, Canada, Australia, and Japan.[24][25][26][27] It is not approved by the European Medicines Agency (EMA) for use in the European Union or by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.[28][29]
Research
Lemborexant is under development for the treatment of
References
- ^ a b "Dayvigo". Therapeutic Goods Administration (TGA). 23 July 2021. Retrieved 5 September 2021.
- ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Retrieved 13 May 2022.
- ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad "Dayvigo- lemborexant tablet, film coated". DailyMed. Retrieved 17 June 2021.
- ^ "Summary Basis of Decision (SBD) for Dayvigo". Health Canada. 23 October 2014. Retrieved 29 May 2022.
- ^ ISSN 0377-8282.
- ^ PMID 32666570.
- ^ S2CID 221572078.
- ^ S2CID 235321467.
- ^ "Novel Drug Approvals for 2019". U.S. Food and Drug Administration (FDA). 2 January 2020. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
- ^ "FDA-Approved Drugs: Lemborexant". U.S. Food and Drug Administration (FDA). Retrieved 10 January 2020.
- ^ a b "FDA Approves Dayvigo (lemborexant) for the Treatment of Insomnia in Adult Patients". Drugs.com. 23 December 2019. Retrieved 10 January 2020.
- ^ S2CID 248119793.
- PMID 35298826.
- ^ S2CID 250536370.
- PMID 34422270.
- PMID 32022664.
- S2CID 238476630.
- PMID 25489915.
- PMID 26045032.
- S2CID 21106711.
- ^ PMID 34553844.
- ^ "Lemborexant". Specialist Pharmacy Service. Archived from the original on 7 November 2017. Retrieved 5 November 2017.
- ^ "Drug Trials Snapshot: Dayvigo". U.S. Food and Drug Administration (FDA). 20 December 2019. Retrieved 24 January 2020. This article incorporates text from this source, which is in the public domain.
- ^ "Micromedex Products: Please Login".
- ^ "Drug Product Database: Access the database". 18 March 2010.
- ^ "Dayvigo". 23 July 2021.
- ^ "EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO® (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN | News Release:2020 | Eisai Co., Ltd".
- ^ "Medicines". European Medicines Agency.
- ^ "Products". Medicines and Healthcare products Regulatory Agency (MHRA).
- ^ a b "Lemborexant - Eisai - AdisInsight".